Telmisartan in daily clinical practice: Factors affecting efficacy in treatment of primary arterial hypertension

Journal of Postgraduate Medicine

Volumn 55, Issue 1, 2009, Pages 27-32

  Bergovac, M ^a   Knezevic A ^b   Plavec, D ^c   Trkulja, V ^d  

^a University of Zagreb   (Croatia)

^b Department of Internal Medicine   (Croatia)

^c INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Daily practice; Essential hypertension; Predictors; Telmisartan

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; IMPOTENCE; INDUCED HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; OBESITY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TREMOR; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 61649102014     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.43547     Document Type: Article

References (16)

1. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in management of hypertension and related disorders. J Hypertens 2007;25:25-35.
2. Battershill AJ, Scott LJ. Telmisartan: A review of its use in the management of hypertension. Drugs 2006;66:51-83.
3. Pritor® tablets (telmisartan) Scientific discussion. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Pritor/198798en6.pdf. [last accessed 2008 July 10].
4. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003;254:105-13.
5. Dans LA, Dans LF, Guyatt GH, Richardson S. User's guide to the medical literature. How to decide on the applicability of clinical trial results to your patient? JAMA 1998;297:545-9.
6. Pritor® (telmisartan) Summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Pritor/H-210-PI-en.pdf. [last accessed 2008 July 14].
7. Materson BJ. Variability in response to antihypertensive drugs. Am J Med 2007;120:S10-20.
8. Klocke RK, Landen H. Treatment of hypertension in daily practice: Current results of a postmarketing surveillance study with telmisartan. MMW Fortschr Med 2007;149:59-67.
9. Ingino C, Farsang C, Laucevicius A, Bergovec M. An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J Intern Med Res 2004;31:561-74.
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002;6:393-404.
11. Gil-Extremera B, Ma PT, Yulde J, Kalnins U, Harkin N, Williams L. The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. Int J Clin Pract 2003;57:861-6.
12. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004;44:12-9.
13. Ernsberger P, Koletsky JR. Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect? Curr Opinion Pharmacol 2007;7:140-5.
14. Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/ hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study. Cardiovasc Diabetol 2007;6:28.
15. Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27:335-44.
16. Giles TD, Bakris GL, Smith DH, Davidai G, Weber MA. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003;16:460-6.